15-16 November, 2013
18-20 October, 2013
IEP 2013 European Spine Fellows and Young Surgeons Course Sponsorship
9-12 October, 2013
New Orleans, USA
02-04 October, 2013
Liverpool, United Kingdom
18-21 September, 2013
13-15 June, 2013
29 May - 1 June , 2013
16-18 May, 2013
7 May, 2013
SpineVision® SA Raises $10m and Adds New Investors
27 April -1 May 2013
2013 AANS Annual Scientific Meeting
New Orleans, Luisiana
22-23 March, 2013
45 ème Congrès du GES
License provides SpineVision® with clinically proven polyurethane biomaterial to enhance flexibility and compression in posterior lumbar pedicle screw systems
Berkeley, CA – March 19, 2012
DSM, a global leader in biomedical materials science, today announced that the company has signed a license and supply agreement with spinal implant and surgical systems developer, SpineVision®.
The agreement grants SpineVision® the use of Bionate® II PCU, a proprietary DSM polymer, in its new Flex+2™ system. The system is adaptable to the various stages of disc degeneration from early degeneration of intervertebral discs to total disc degeneration requiring fusion procedures. This level of flexibility not only offers spine surgeons more options in the treatment of lumbar disc diseases, but also allows selective segmental stabilization to better treat disc degeneration throughout multiple stages.
The Flex+2™ system utilizes a top-loading, top-tightening design, which accommodates both open and percutaneous approaches. DSM’s Bionate® II PCU encapsulates the metal wire and provides the system with enhanced frontal and sagittal stabilization, assuring flexion and extension, which allow for increased freedom of movement and better accommodation to the spine without loss of strength or stability.
“The combination of design changes and the use of Bionate® II PCU have enabled SpineVision® to enhance the mechanical capabilities of the new Flex+2TM system leading to extended indications” said Arnaud Brisard, Chief Executive Officer, SpineVision®.
“DSM’s polyurethane materials have a proven clinical history and have been used in several dynamic stabilization devices and implants,” said William Fuller, Director of Business Development, DSM Biomedical. “Our Bionate® II PCU provides increased flexibility and shock absorbing characteristics, replicating the natural movements of the spine. We are proud to see Bionate® II PCU contributing to the performance of SpineVision’s Flex+2™ system.”
SpineVision® will initially launch the Flex+2™ system in the European Union. The device is not currently available for sale in the U.S.
DSM – Bright Science. Brighter Living.™ Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences, DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 23,500 employees deliver annual net sales of around €9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.
9-10 November, 2012
24-27 October, 2012
11-14 October, 2012
7-9 June, 2012
7ème congrès de la SFCR Strasbourg, France
1-2 June, 2012
28 May-1 June, 2012
17-19 May, 2012
2-4 May, 2012
14-18 April 2012
2012 AANS Annual Scientific Meeting
Miami, Floride USA
23-24 March, 2012
44 ème Congrès du GES
14-16 March 2012
l’Orthopédie Infantile et la Rééducation
February 2012 - Benelux : Benelux Country Manager
Danny Severens joined SpineVision Belgium as Benelux Country Manager.
Danny has more than 13 years of sales experience in Medical Devices and Pharmaceuticals.
He comes to SpineVision after more than 4 years with Synthes Spine where he served as Sales Manager.
Prior to this, he held several sales positions in the Medical Industry.
December 2011 – HQ : R&D Manager
Alexandre Capron has joined SpineVision SA as R&D Manager.
Alexandre has more than 6 years of R&D experience in spinal implants. Before joining SpineVision, Alexandre managed R&D Project teams during 2 years within Alphatec and 4 years within Scient’X.
October 2011 – UK : UK & Ireland Sales Manager
Nicholas Kennedy joined SpineVision Ltd as UK & Ireland Sales Manager.
Nik has more than 16 years of experience in Sales of medical devices and comes to SpineVision after 8 years with DePuy Spine where he served as UK Sales and Product Manager.
Prior to this, he held several sales positions in the medical area.
September 2011 – US : North American Sales Manager
Mindy Anderson joined SpineVision Inc. as North American Sales Manager.
Mindy has more than 10 years of sales experience in Medical Devices and Pharmaceuticals, among which more than 4 years’ experience in Spine in the US.
Mindy comes to SpineVision after 2 years with Globus Medical where she was Spine Specialist and prior to this she spent 2 years with Medtronic where she served as Therapy Consultant.
Mindy has also 6 years of experience in Pharmaceuticals in the US.
SpineVision announced today that it has raised $5 million from existing investors, one new investor, and Company management. The cash infusion will be used primarily to accelerate market penetration of the Company’s next-generation devices for spinal treatment : (1) the minimally invasive system LUMIS™ and (2) the motion-preservation hybrid-rod system Flex+™.
SpineVision has relocated its Headquarters to Antony Parc II – 10 Place du Général de Gaulle – 92184 Antony Cedex (Haut de Seine), in the south suburb of Paris. Our new offices are easily reachable by car and public transportation, and at a 10/15 min. drive only to Orly International Airport.
© 2011 - 2012 SpineVision®. All Rights Reserved. | Legal information